CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
December 2017—Agena Bioscience announced a comparative study published in PLOS One (Sutton BC, et al. 2017;12[9]:e0183715) highlighting the use of its mass-spectrometry-based platform and iPlex HS chemistry for detection of somatic mutations in EGFR, KRAS, BRAF, and NRAS occurring in non-small cell lung cancer.
In this proof-of-principle study, 179 archived clinical specimens of NSCLC from the Medical Foundation were tested using Agena Bioscience’s iPlex HS Lung Panel, which has a limit of detection of one percent variant allele frequency and requires only 5–10 ng of input DNA. The specimens were previously tested for EGFR, KRAS, NRAS, and BRAF mutations using the company’s OncoFocus v 2.0 or v 3.0 panels on the MassArray System, which have a limit of detection of five to 10 percent VAF. With the increased sensitivity of the iPlex HS chemistry, an additional 17 (or 9.5 percent more mutations) previously undetected KRAS, NRAS, BRAF, and EGFR mutations were identified. These additional mutations were mostly detected in core needle biopsies and cytology cell blocks.
Agena Bioscience, 858-882-2800